Vitrectomy in full thickness macular holes on top of a pigment epithelial detachment in age-related macular degeneration (AMD). Surgical consideration and review of the literature

Paula S. Meyer, Marc T. Kammann, Carsten H. Meyer

Macular Center Davos, Switzerland

ARTICLE INFO

Keywords:
Vitreomacular traction
Macular hole
Pigment epithelial detachment
Age-related macular degeneration
Vitreoretinal surgery
Epiretinal membrane

ABSTRACT

Purpose: To present the surgical treatment of a full thickness macular hole (MH) caused by a vitreomacular traction (VMT) on top of an adjacent subfoveal pigment epithelial detachment (PED) in age-related macular degeneration (AMD).

Observation: A 77-year-old female with a subfoveal PED receiving consecutive intravitreal injections noticed a sudden decreased visual acuity (VA) due to the development an occult MH in her right eye after 19 repeated intravitreal anti vascular endothelial growth factor (VEGF)-injections. Her initial VA declined from 20/50 to 20/400. The firm VMT induced a rupture of the multi-layered retina and may progress to an RPE-tear or possible to a subretinal haemorrhage. We discussed with the patient the risks of the natural progression and explained possible treatment options: We continued her anti-VEGF combined with air bubble injections to induce a posterior vitreous detachment, to stabilise the retinal architecture, reduce the subretinal fluid and avoid possible intraoperative bleeding. As injections did release the VMT, vitrectomy released the posterior vitreous from the optic nerve and trimmed it towards the central retina. Peeling with brilliant blue removed the internal limiting membrane without any signs of bleeding, rupture of the PED or enlargement of the MH, prior to the installation of 10% SF6 gas. The postoperative optical coherence tomography (OCT) on day 5 confirmed a closed MH, while the size, shape and pattern of the PED remained unchanged. Her VA increased from 20/400 to 20/50 (equal to her previous VA prior to the MH-formation). To avoid a potential progression of the PED, we maintained her retreatment intervals at 5 weeks for the next 6 months. A literature review presents similar intraoperative approaches and postoperative outcomes in 8 out of the 9 published cases.

Conclusions and importance: VMT can induce an occult MH on top of a PED, causing a significant loss of vision. When gas injections are not successful, surgery may release the traction, restore the retinal architecture, and significantly improve and maintain the VA over a documented long-term observation. The epiretinal procedure should be assisted under regular anti-VEGF injections to maintain the subretinal architecture.

1. Introduction

Vitreomacular traction (VMT) may occur during aging from incomplete posterior vitreous detachment (PVD) with remaining adhesions at the central macula, leading to the formation of a macular hole (MH) or cystoid oedema. While VMT has also been observed in conjunction with different stages of age-related macular degeneration (AMD), it may have an impact on the progression from non-to exudative AMD in selected patients. Many eyes with incomplete PVD present particularly firm vitreopapillary adhesions at the optic nerve head and central fovea; thus, any contraction between these two firm adhesions may induce a vector of share traction from the fovea towards the optic nerve head, explaining why many pigment epithelial detachments (PED) typically rupture at their temporal edge towards the centre. However, the concurrent occurrence of a VMT adjacent to a PED can also lead to full thickness MH-formation in rare cases. The coincidental development of such an occult MH on top of a PED will lead to unexplained vision loss. Previously, we described this phenomenon as a natural cause or after consecutive intravitreal injections. While small idiopathic MH may close spontaneously, their presence on top of a PED in conjunction with very firm VMT appears to persist predominantly, possibly progressing to a secondary subretinal (SR) pigment epithelial...
Here, we demonstrate the surgical release of a persisting VMT in an MH over a subfoveal PED to discuss possible considerations in the preoperative preparation and intraoperative approach of our case, and to compare our postoperative outcome with the few published cases of this rare entity and approach.

2. Case report

A 77-year-old female with neovascular AMD and chronic PED OD had been treated with 19 intravitreal anti-vascular endothelial growth factor (VEGF)-injections over the course of 3 years. On optical coherence tomography (OCT) there was a significant PED with some SR fluid prior to each injection. Over time, we noticed an occult VMT at the foveal centre, which became evident when the retinal was thin soon after each anti-VEGF injection. Her visual acuity (VA) remained stable at 20/50 under this treatment regime, until she presented a sudden decrease of VA in her right eye from 20/400. On dilated fundus biomicroscopy, as well as standard OCT-scanning, no AMD-progression was apparent. A meticulous thin lined en face OCT-examination revealed an unchanged pattern of the PED, while a MH with a VMT on top of the PED became visible (Fig. 1a). This tiny but full thickness occult MH with a diameter of 568 μm may have been responsible for the decreased VA, so we discussed further treatment options with our patient. The presence of the firm VMT had already induced the rupture of the multi-layered retina; thus, an additional rupture of the PED monolayer of the RPE may progress to an RPE-tear and possible SR haemorrhage with a consecutive loss of the remaining VA. We discussed the risks of natural progression with the patient and explained possible treatment options: At first, we combined the next intravitreal anti-VEGF injections with a consecutive 1 cc air bubble application and asked the patient to maintain in a prone position over night and was examined during the next few days. The intraocular gas bubble vanished over 5 days and her intraocular pressure remained normal at 18 mmHg. The OCT on her 5th postoperative day revealed a closed MH, while the size, shape and pattern of the PED had not changed (Fig. 1b). During the 6-month follow-up period, her right eye developed no RPE-tear formation of the SR haemorrhage. To avoid progression of the PED and with respect of the altered pharmacokinetics of the anti-VEGF drug in the vitrectomized vitreous cavity, we maintained her retreatment intervals at 5 weeks for the next 6 months. Her VA increased from 20/400 to 20/50 (equal to her previous VA prior to the MH-formation and she was able to read again).

3. Discussion

The aging vitreous may play an important role as a coincident factor in the pathogenesis of numerous macular diseases. While VMT is a potential risk for exudative AMD, it may also reduce the efficacy of anti-VEGF injections, requiring more frequent retreatments during the extension period. The higher age of the elderly patient and the
architecture of the vitreoretinal interface showed signs of firm adhesions with a low probability of spontaneous separation, considering a surgical release in this case. The concurrent presence of MH and CNV has been evaluated in the past. In 2001, Elsing et al. reviewed the surgical outcome of such cases with 20-gauge instruments by combined MH-repair and CNV-removal, and reported a final VA, ranging from 20/100 to hand motions, limited by the cumulative retinal and RPE damage. More recently, Hirata et al. reported the removal of a CNV-membrane with 25-gauge instruments through the coincident presence of a macular hole after anti-VEGF therapy for AMD and observed a rapid resolution of the intraretinal macular oedema with a fast anatomical and functional recovery to 20/40.

The development of MH after intravitreal injections has been described in the past in eyes with the primary diagnosis of neovascular AMD, diabetic macular oedema, branch retinal vein occlusion or vasoproliferative tumours. In addition to their primary vascular exudation, most eyes present signs of epiretinal traction or VMT, predisposing tangential or anteroposterior traction after each injection. Several epiretinal or SR mechanisms may trigger the formation of MH after intravitreal injections: first, the applied volume of fluid and its chemical compounds modify and liquefy the structure of the vitreous gel (syneresis), leading to incomplete PVD and anteroposterior traction on the VMT. Second, Grigoropoulos et al. hypothesised that the mechanical insertion of the injection needle leads to a globe deformation and retinal traction, while the removal of the needle may cause a consecutive vitreous micro-incarceration exacerbating the underlying VMT. Previously, we also analysed and calculated the initial release velocity of an injected Ozurdex implant by a high-speed camera and determined that the dragging force of the vitreous gel decelerates the implant, thus avoiding damage to the retinal surface. In addition, the contraction of the CNV complex and flattening of the PED may create an anterior-posterior vectorial force diametrically opposite to the direction of the overlying VMT, thus increasing the risk for a retinal defect, and contributing to formation of a MH. Finally, the aim of the potent anti-VEGF drug is to modulate the activity of the CNV, inducing a rapid contraction of the vasoproliferative membrane with forces on the CNV and PED, with tangential traction on the overlying retina. Combined MH and RPE-tear may therefore both rely on a contraction of the RPE as the exacerbating factor.

Our case also presented the simultaneous presence of two separate pathologies below and above the retina, requiring additional well-considered proceedings:

1. The chronic underlying SR PED must be sufficiently treated by ant-VEGF injections. An active lesion may potentially cause SR bleeds, during either the surgical manipulation of the adjacent epiretinal VMT or the postoperative period. An undertreated PED prior to surgery may also cause significant SR fluid accumulation, making the neuroretina less compact and resistant to the presumed tractions shear force during the epiretinal ILM-peeling.

II. Any systemic aspirin or warfarin application should be interrupted, if possible, prior to and shortly after the surgery.

III. The stepwise intraoperative release of the epiretinal traction needs to be well-thought out and structured ahead of surgery:

- The vitreous removal on top of such a delicate lesion requires a gentle and slow intentional removal of the vitreous with a high cutting rate and low aspiration, diminishing any possible traction on the perpendicular retinal lesion as much as possible.
- Chromovitrectomy with triamcinolone may help to stain and visualise the posterior hyaloid for its safe and reliable removal.
- The release of the posterior hyaloid should not start with the VMT itself, as unexpected firm adhesions may induce traction and vigorous force of the PED, possibly inducing a rupture of the thin RPE-monolayer or adjacent choroidal vessels causing a vision threatening subretinal haemorrhage. We recommend initiating the induction of PVD at first over the optic nerve head to release the vitreopapillary adhesion followed by trimming the posterior hyaloid only partially over the macular area.
- Another consideration prior to surgery may be pneumatic vitreolysis by the intravitreal application of C3F8 gas to relieve vitreous traction and possibly close the macular hole.
- Finally, we discussed whether a plain PVD may be enough to seal the MH on top of the PED, as many small conventional MHs close after a solely PPV without an ILM-peel.

However, we decided to intraoperatively stain and visualise the ILM with the application of brilliant blue by chromovitrectomy. We observed a well-delimited ILM and started an attempt to remove it at the outer macular area close to the vascular arcade, where the retina was not perpendicular to the fragile PED. We noticed a well-controlled, gentle release of the ILM and decided to extend the peeling in a slow manner from the periphery of the outer macula towards the rim of the MH. This manoeuvre should be avoided if the ILM presents firm adhesions, as small MH frequently close after the release of the VMT. The eye was closed after a conventional fluid-air-exchange and a fast conventional closure of the small MH presented within days. Once the epiretinal pathology has been treated, continuous retreatments of the subretinal PED with consecutive monthly anti-VEGF injections are recommend, as the pharmacokinetic durability of the fluid anti-VEGF drug may be reduced after removal of the vitreous according to previous measurements. On the one hand may the release of the vitreous traction reduce the activity of the CNV and frequency of consecutive injections, on the other hand we may face a shortened durability of the liquid drug in any vitrectomized vitreous cavity. Finally, in any eyes with the unexplained
onset of new symptoms, we recommend extending the conventional 12-line radial OCT-scan to a raster en face OCT-examination to detect tiny occult lesions, which may have remained undetected with conventional OCT-protocols.\(^{26}\)

While several papers described the rare development of MH after intravitreal injections in greater detail postulating the underling pathomechanism,\(^{3–5,25}\) only 9 reported eyes have been treated by PPV (Table 1): This was a 67-year-old female with a subfoveal PED and adjacent occult CNV. During the full up-loading phase by three uneventful intravitreal ranibizumab injections, she developed an accelerating VMT and finally an MH on top of the PED. The vitreous traction was released during PPV and ILM-peeling, and her hole closed postoperatively, while the PED remained consistent. Today, with a documented 10-year follow-up we can address also important additional information regarding the long-term prognosis for the discussion of these rare eyes: The analysis of our consecutive OCT images (Fig. 2a-d) between our PPV in October 2009 and the latest follow-up in April 2021 shows a gradual anatomical closure of the macular hole over 4 years postoperative period (Fig. 2c), while the macular hole did not reopen at any time. In addition, the heights of the measured subretinal PED maintained constant over the next 6 years (Fig. 2d) and was controlled by repeated intravitreal injections. The annual frequency of the applied intravitreal injections did not differ in the previously non- vitrectomized PED with the VMT (n = 6 per year) prior to the vitrectomy, compared to the here vitrectomized eye with a PED after the released VMT (n = 5–6 injections per year). The measured retinal thickness remained stable under anti-VEGF therapy. However, we observed a constant progression of drusen associated with a gradual expanding area of the PED, corresponding with a progression of the underlying disease, while the heights of the PED itself gradually declined under the anti-VEGF therapy (Fig. 2e). The RPE layer of the PED maintained intact, no bleedings or RPE-tear occurred during the documented 10-year follow-up, while her postoperative VA declined by one line during this period.

Our findings correlate with most of the published cases\(^ {7,29–36}\): most surgeons determined a small MH on the preoperative OCT, with frequent signs of ERM or VMT, undermining vitreous tractions as a causative factor. They also predominantly performed a PPV with a consecutive ILM-peel and gas tamponade. All but one MH closed, and no surgeon reported an RPE-tear formation or SR haemorrhage intra- or post-operatively. Thus, overall, the detached RPE-monolayer appears to be strong and elastic enough to resist an ILM-peeling. No MH demonstrated a late reopening after PPV. All the treated eyes experienced some functional improvement up to the best corrected VA prior to the MH-formation. These are important information encouraging a surgical treatment of a MH on top of a PED.

4. Conclusions

The treatment of eyes with PED and VMT or ERM under anti-VEGF injections may, in rare cases, induce a small but full thickness MH-formation. These rare sequelae of occult MH are frequently associated with an unexplained decrease in central vision, requiring intense raster OCT-evaluations. Our case is complementary to others describing the surgical closure of full thickness MHs on PED-lesions after PPV with ILM-peeling. Treatment remains challenging but appears to be safe if caution is considered.

### Authorship

All authors state that they meet the current ICMJE criteria for Authorship.

### Authors’ contributions

All authors read and approved the final manuscript.

---

**Table 1**

| Eyes     | Reference                          | Patient age, gender | Ocular diagnosis                      | Previous treatment | VA preop | VA postop | Macular hole (stage) | Surgery | Complication | Follow-up months |
|----------|------------------------------------|---------------------|---------------------------------------|--------------------|----------|-----------|---------------------|---------|-------------|------------------|
| 1        | Sato A. et al. 2020\(^{37}\)        | 64-years, male OD, VMT, SRF, vasoproliferative Tx, | 2x IVB | 20/25 | 20/63 | IV | phaco, 25g ppv, ILM peeling, 25% SF6 | closed, no hem | 12 |
| 2        | Mukherjee et al. 2015\(^{19}\)      | 81-years, male OD, VMT, PED | 3x IVR | 6/30 | 6/24 | III | phaco, macular hole surgery | na | na |
| 3        | Lee YJ, Kim K. 2019\(^{11}\)        | 62-years, female OS, VMT, CNV | 2x IVR | 6/24 | 6/36 | III | phaco, macular hole surgery | na | na |
| 4        | Muramatsu D. et al. 2015\(^{25}\)   | 56-years, male OD, ERM, DME | 1x IVB | 20/200 | 20/100 | IV | phaco, 25g ppv, ILM peeling, 20% SF6 | closed, serous RD, no hem | 6 |
| 5        | Shif OA, Katz MSJ. 2018\(^{18}\)    | 63-years, male OD, ERM, BRVO, SRF, | IVR | 20/200 | 20/40 | IV | phaco, 25g ppv, ILM peeling, 20% SF6 | Closed no hem | 5 |
| 6        | Raji VR, Eliott D, Sadda SR. 2013\(^{14}\) | 77-years, male OD, RPE-tear | IVR | 20/200 | 20/60 | IV | phaco, 16% C3F8 | na | na |
| 7        | Regatiere CV, Ducker JS. 2012\(^{12}\) | 69-years, female OS, VMT, PED | IVR | 20/200 | 20/60 | IV | phaco, ILM peeling, gas ppv, ILM peeling, gas | no hem | open |
| 8        | Clemenc C, Holz FG, Meyer CH. 2010\(^{7}\) | 76-years, male OD, VMT, CNV | 1x IVR | not improved | | | | | |
| 9        | Meyer PS, Kammann MT, Meyer CH. 2021\(^{7,29}\) | 67-years, female OS, VMT, PED | 3x IVR | 20/30 | 20/30 | III | 23g ppv, ILM peeling, 20% SF6 | closed, no hem | 12 |

**Abbreviations:** OD oculus dexter, OS oculus sinister, VA visual acuity, VMT vitreomacular traction, Tx tumor, SRF subretinal fluid, PED pigment epithelial detachment, CNV choroidal neovascularization, BRVO branch retinal vein occlusion, DME diabetic macular oedema, RPE retinal pigment epithelium, IVB intravitreal bevacizumab, IVR intravitreal ranibizumab, ILM inner limiting membrane, ppv pars plana vitrectomy, phaco phacoemulsification, SF sulfur hexafluoride, hem haemorrhage.
Fig. 2a. Historic 10 years long-term vertical OCT-scans of a closed macular hole on top of a PED after vitrectomy: A preoperative status of a PED with a height of 256 μm with a perpendicular macular hole with an aperture of 320 μm and a vitreomacular traction.

Fig. 2b. Six months postoperative status of a PED with an unchanged height of 258 μm, an outer retinal closure of the macular hole, retinal thickness 134 μm and a vitreomacular traction.

Fig. 2c. Four years postoperative status of a PED with a similar height of 235 μm, an outer retinal closure of the macular hole, retinal thickness 159 μm.
Funding

There was no funding or grant support.

Patient consent

Consent to publish the case report was obtained. This report does not contain any personal information that could lead to the identification of the patient.

Sample credit author statement

Paula S Meyer: Original draft preparation, Image collection, Formal analysis, Writing-. Marc T Kammann: Reviewing, Editing and Visualization, Carsten H. Meyer: Image analysis, Conceptualization, Methodology, Supervision, Reviewing.

Declaration of competing interest

All authors have no financial disclosures.

Acknowledgements

The authors thank Prof. Frank G. Holz to allow us the inclusion of the well-documented long-term images in Fig. 2 from the University of Bonn.

References

1. Sebag J. Anomalous posterior vitreous detachment: a unifying concept in vitreoretinal disease. Graefes Arch Clin Exp Ophthalmol. 2004 Aug;242(8):690–698. https://doi.org/10.1007/s00417-004-0980-1.
2. Robison CD, Krebs I, Binder S, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol. 2009;148:79–82.
3. Schulze S, Hoerle S, Mennel S, Kroll P. Vitreomacular traction and exudative age-related macular degeneration. Acta Ophthalmol. 2008 Aug;86(5):470–481. https://doi.org/10.1111/j.1755-3768.2008.01210.x.
4. Sebag J, Wang MY, Nguyen D, Sadun AA. Vitreopapillary adhesion in macular diseases. Trans Am Ophthalmol Soc. 2009 Dec;107:35–44.
5. Chan CK, Abraham P, Meyer CH, et al. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina. 2010 Feb;30(2):203–211. https://doi.org/10.1097/IAE.0b013e3181babda5.
6. Meyer CH, Mennel S. Vitreomacular traction, macular hole formation, and subfoveal choroidal neovascularization in a patient with age-related macular degeneration. Eye. 2006;20:1090–1092.
7. Clemens CR, Holz FG, Meyer CH. Macular hole formation in the presence of a pigment epithelial detachment after three consecutive intravitreal antivascular endothelial growth factor injections. J Ocul Pharmacol Therapeut. 2010 Jun;26(3):297–299. https://doi.org/10.1089/jop.2009.0140.
8. Meyer CH, Toth CA. Retinal pigment epithelial tear with vitreomacular attachment: a novel pathogenic feature. Graefes Arch Clin Exp Ophthalmol. 2001 Jun;239(5):325–333. https://doi.org/10.1007/s004170100259.
7

Garcia JH, Johnson M, Shah G, et al. Macular microhole and foveal red spot syndrome: a critical review of the literature. Graefes Arch Clin Exp Ophthalmol. 2020 Nov 2. https://doi.org/10.1007/s00417-020-09495-z.

Mennel S, Meyer CH, Schmidt JC. The role of the vitreous in the pathogenesis of age-related macular degeneration. Klin Monbl Augenheilkd. 2011 May;228(5):460–464. https://doi.org/10.1055/s-0030-1245464.

Krebs I, Brennath W, Glittenberg C, Zeiler F, Sebag J,Binder S. Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol. 2007 Nov;144(5):741–746. https://doi.org/10.1016/j.ajo.2007.07.026.

Suzuki H, Morishita S, Kohmoto R, et al. Effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection. Clin Ophthalmol. 2017 Aug 11;11:1471–1475. https://doi.org/10.2174/1875358511711083001.

Meyer CH, Rodrigues EB, Mennel S, Schmidt JC, Kroll P. Spontaneous separation of epiretinal membrane in young subjects: personal observations and review of the literature. Graefes Arch Clin Exp Ophthalmol. 2004 Dec;242(12):977–985. https://doi.org/10.1007/s00417-004-0934-7.

Paul C, Heun C, Müller HH, et al. Impact of vitreoretinal interface architecture on successful vitreomacular traction resolution in eyes scheduled for intravitreal ocirplalin therapy. Retina. 2017 Jul;37(7):1252–1260. https://doi.org/10.1097/IAE.0000000000001271.

Elshing SH, Postel EA, Gill MK, Jampol LM, Jaffe GJ. Management of eyes with both idiopathic macular hole and choroidal neovascularization. Retina. 2001;21:613–618.

Hiata A, Hayashi K, Murakata K, Nakamura KI. Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration. Am J Ophthalmol Case Rep. 2017 Dec 19;9:14–17. https://doi.org/10.1016/j.ajocrc.2017.12.003.

Gillard R, Shani P, Achia N, et al. Full thickness Macular hole in AMD patients two distinct entities? Multicenter study. Retina. 2021. https://doi.org/10.1097/IAE.0000000000001314, February 01, 2021 — Volume Publish Ahead of Print — Issue -. In press.

Querques G, Souied EH, Soubrane G. Macular hole formation following intravitreal ranibizumab injection for choroidal neovascular membrane caused by age-related macular degeneration. Acta Ophthalmol. 2009;87(2):235–237.

Moiniev E, Goldstein M, Loewenstein A, Moiniev J. Macular hole following intravitreal bevacizumab injection in choroidal neovascularization caused by age-related macular degeneration. Case Rep Ophthalmol. 2010 Aug 18;1(1):36–41. https://doi.org/10.1159/000191827.

De Benedetto U, Battaglia Parodi M, Knutsson KA, Lattanzio R, Bandello F, Iacono P. Macular hole after injection of dexamethasone intravitreal implant for macular oedema due to central retinal vein occlusion. Acta Ophthalmol. 2013 Feb;91(1):e75–e77. https://doi.org/10.1111/j.1755-3768.2012.02484.x.

Oshina Y, Apte RS, Nakao S, Yoshida S, Ishibashi T. Full-thickness macular hole case after intravitreal aflibercept treatment. BMC Ophthalmol. 2015 Mar 29;15:30. https://doi.org/10.1186/s12886-015-0021-3.

Kabanarou SA, Xirou T, Mangouritsas G, et al. Full-thickness macular hole formation following anti-VEGF injections for neovascular age-related macular degeneration. Clin Interv Aging. 2017 May;12:911–915. https://doi.org/10.2147/CIA.S135364.

Sethia A, Sethi J, Gopalakrishnan M, Anantharaman G. Spontaneous formation and closure of full thickness macular hole after treatment with anti-vascular endothelial growth factor therapy in polyoidial choroidal vasculopathy. Indian J Ophthalmol. 2019 Oct;67(10):1756–1758. https://doi.org/10.4103/ijop.IJO_1597-18.

Costa Edén P, Rodrigues EB, Farah ME, et al. Novel vitreous modulators for pharmacologic vitreolysis in the treatment of diabetic retinopathy. Curr Pharmaceut Biotechnol. 2011 Mar 1;12(3):410–422. https://doi.org/10.2174/1389201111794480516.

Grigoropoulos V, Efremitzoglou J, Nikolaou P, Theodosiadis G, Theodosiadis P. Full-thickness macular hole after intravitreal injection of ranibizumab in a patient with retinal pigment epithelium detachment and tear. Eur J Ophthalmol. 2010 Mar-Apr;20(2):469–472. https://doi.org/10.1177/101713961002000235.

Meyer CH, Klein A, Alten F, et al. Release and velocity of micronized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed camera. Retina. 2012 Nov-Dec;32(10):2133–2140. https://doi.org/10.1097/IAE.0b013e31825269e5.

Krohne TU, Liu Z, Holz FG, Meyer GH. Intravascular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012 Oct;154(4):682–686. https://doi.org/10.1016/j.ajo.2012.03.047.

Adam MK, Shahlaee A, Samara WA, Maguire JI, Ho AC, Hsu J. En face versus 12 line radial optical coherence tomography scan in neovascular age-related macular degeneration. Retin Cases Brief Rep. 2020 Winter;14(1):53–60. https://doi.org/10.1097/ICB.0000000000000616.

Sato A, Fukui E, Obha K. Macular hole formation in eye after cryotherapy and intravitreal bevacizumab treatment for vasoproliferative tumor. Int Med Case Rep J. 2020 Sep 14;13:413–423. https://doi.org/10.2147/IMCRJ.S266986. eCollection2020.

Mukherjee C, Mirza A, Kumar NA, Elsherbiny S, Lip PL. Macular hole formation after intravitreal ranibizumab injection in wet age-related macular degeneration. Open Ophthalmol J. 2015 Dec 31;9:177–180. https://doi.org/10.2174/1873484109010177.

Lee YJ, Kim M. Macular hole formation after intravitreal injection of bevacizumab for diabetic macular edema. Kor J Ophthalmol. 2019 Apr;33(2):198–199. https://doi.org/10.3341/kjo.2018.0079.

Muramatsu D, Mitsuhashi R, Iwasaki T, Goto H, Miura M. Macular hole formation following intravitreal injection of ranibizumab for branch retinal vein occlusion: a case report. BMC Res Notes. 2015 Aug 19;8:358. https://doi.org/10.1186/s13104-015-1324-4.

Shif OA, Katz MSJ. Surgical management of full thickness macular hole superimposed on exudative age-related macular degeneration. Retin Cases Brief Rep. 2018 Aug 7. https://doi.org/10.1016/j.icb.2018.05.00786.

Raij VR, Elliott D, Sadda SR. Macular hole overlying pigment epithelial detachment after intravitreal injection with ranibizumab. Retin Cases Brief Rep. 2013 Winter;7(1):91–94. https://doi.org/10.1097/ICB.0b013e318260956d.

Regatierv CV, Duker JS. Bilateral macular hole after anti-vascular endothelial growth factor therapy in a patient with exudative age-related macular degeneration. Retin Cases Brief Rep. 2012 Winter;6(1):125–128. https://doi.org/10.1097/ICB.0b013e3182169592.

Nawrocka Zofia Anna, Nawrocka Zosia, Nawrocki Jerzy. Vitrectomy for full thickness macular hole developed during the course of anti-VEGF treatment of type 1 neovascular AMD. Eur J Ophthalmol. 2021. https://doi.org/10.1177/11206721211002123. Online ahead of print. In press.